Tiger's Take
We are moving away from the era of "one size fits all" orthopedics. We’ve mastered the metal and plastic; now we have to master the immunology.
ExplantLab is the first company to give surgeons a practical, scalable way to screen for biological compatibility. When they hit the US market, I expect to see rapid adoption from high-volume centers of excellence and ASCs that want to drive their revision rates down to zero.
If you’re a surgeon, an investor, or an implant rep, keep your eyes on ExplantLab. The "Mystery Pain" era is coming to a close, and the era of Immunological Orthopedics is beginning.
We’ve spent decades obsessing over mechanics. We talk about bearing surfaces, fixation, robotic precision, and wear rates. But even with the most perfectly placed implant, there is a ghost in the machine that the industry has largely ignored: The Patient’s Biology.
I recently sat down (virtually) to dive into the work being done by Dr. David Langton and the team at ExplantLab. If you aren’t familiar with them yet, pay attention. Based in the UK, ExplantLab is doing the deep forensic and biological work that the orthopedic industry has needed for twenty years.
As they prepare ...
